ATE254172T1 - Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase - Google Patents

Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase

Info

Publication number
ATE254172T1
ATE254172T1 AT94103057T AT94103057T ATE254172T1 AT E254172 T1 ATE254172 T1 AT E254172T1 AT 94103057 T AT94103057 T AT 94103057T AT 94103057 T AT94103057 T AT 94103057T AT E254172 T1 ATE254172 T1 AT E254172T1
Authority
AT
Austria
Prior art keywords
alzheimer
preventive
disease
protein kinase
test method
Prior art date
Application number
AT94103057T
Other languages
English (en)
Inventor
Akihiko Takashima
Toshimitsu Hoshino
Kazutomo Imahori
Ken-Ichi Saito
Akiko Shiratsuchi
Showbu Sato
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27290732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE254172(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP5041160A external-priority patent/JPH06253835A/ja
Priority claimed from JP5191246A external-priority patent/JPH06329551A/ja
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE254172T1 publication Critical patent/ATE254172T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11026—Tau-protein kinase (2.7.11.26)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94103057T 1993-03-02 1994-03-01 Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase ATE254172T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5041160A JPH06253835A (ja) 1993-03-02 1993-03-02 ヒト由来タウプロテインキナーゼｉ、それをコードする遺伝子及びその産生方法
JP8514393 1993-03-22
JP5191246A JPH06329551A (ja) 1993-03-22 1993-08-02 アルツハイマー病の予防または治療薬およびそのスクリーニング方法

Publications (1)

Publication Number Publication Date
ATE254172T1 true ATE254172T1 (de) 2003-11-15

Family

ID=27290732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94103057T ATE254172T1 (de) 1993-03-02 1994-03-01 Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase

Country Status (4)

Country Link
EP (1) EP0616032B2 (de)
AT (1) ATE254172T1 (de)
CA (1) CA2116460A1 (de)
DE (1) DE69433309T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234324T1 (de) * 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
ATE465261T1 (de) * 1995-12-21 2010-05-15 Sunnybrook & Women S College H Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP1019043A4 (de) * 1996-05-07 2003-07-30 Univ Pennsylvania Inhibitoren der glykogensynthese-kinase 3 und verfahren zu ihrer identifizierung und verwendung
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
KR20010079922A (ko) * 1998-09-24 2001-08-22 미우라 아키라 하이드록시플라본 유도체
WO2001021787A1 (fr) 1999-09-17 2001-03-29 Keio University Polypeptide humain responsable de l'inhibition de la mort de cellules nerveuses
US6323029B1 (en) * 2000-01-19 2001-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
AU2001252562A1 (en) * 2000-04-28 2001-11-12 Toshiharu Suzuki Medicinal compositions for suppressing beta-amyloid production
ES2233691T3 (es) 2000-07-27 2005-06-16 F. Hoffmann-La Roche Ag Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de la glicogen sintasa kinasa-3beta.
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
CA2650309C (en) * 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
EP2078717A1 (de) 2008-01-11 2009-07-15 sanofi-aventis 6-Pyrimidinyl-Pyrimid-2-One-Derivate
KR20100074182A (ko) 2007-09-14 2010-07-01 미쓰비시 타나베 파마 코퍼레이션 6-피리미디닐-피리미드-4-온 유도체
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2464639A1 (de) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidonderivate als tau-proteinkinase-1-hemmer
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
EP4567427A1 (de) * 2022-09-01 2025-06-11 Shanghai Raising Pharmaceutical Co., Ltd. Biomarker und zugehöriger nachweiskit für morbus alzheimer

Also Published As

Publication number Publication date
DE69433309T2 (de) 2004-09-16
CA2116460A1 (en) 1994-09-03
DE69433309T3 (de) 2007-08-30
EP0616032B2 (de) 2007-02-14
EP0616032A2 (de) 1994-09-21
EP0616032A3 (de) 1996-12-11
EP0616032B1 (de) 2003-11-12
DE69433309D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
ATE254172T1 (de) Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase
DE59307474D1 (de) Verwendung von wasserlöslichen oder in wasser dispergierbaren polyurethanen als hilfsmittel in kosmetischen und pharmazeutischen zubereitungen und polyurethane, die polymilchsäurepolyole einpolymerisiert enthalten
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
DE69400333D1 (de) Kosmetische und dermatologische Zusammensetzungen, die eine Kombination aus Ceramiden und Linolsäure enthalten
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
EP1014996A4 (de) Zubereitung enthaltende saccharide und methoden zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
BR9610375A (pt) Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69407419D1 (de) 2' oder 3' -deoxy- und 2' -dideoxy-beta-l-pentafuranonukleoside, verfahren zur herstellung und anwendung in der therapie, insbesondere als antivirale wirkstoffe
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
ATE290385T1 (de) Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
Gustafson et al. Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
IT9020968A0 (it) Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
Juhlin et al. Acrivastine Versus Clemastine in the Treatment of Chronic Idiopathic Urticaria.
DE3775854D1 (de) Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
BR9506838A (pt) Derivados de ácido micofenólico substituídos na posição 5
ATE6256T1 (de) N-(4-phenyl-2-thiazolyl)-oxamidsaeure-2ethoxyethylester, verfahren zu seiner herstellung und diesen enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties